Intellia Therapeutics, Inc. (NTLA) is developing its lead in vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. The company is collaborating with Regeneron Pharmaceuticals (REGN) for the development of NTLA-2001. NTLA-2001 is being studied for two indications: ATTR amyloidosis with polyneuropathy (ATTRv-PN) patients and ATTR amyloidosis with cardiomyopathy (ATTR-CM) patients. The phase III MAGNITUDE study evaluating NTLA-2001 to treat ATTR amyloidosis with cardi ...